

GREGORY W. RUTECKI, MD, Section Editor

YAZAN N. ALHALASEH, MD
 Department of Internal Medicine, King
 Hussein Cancer Center, Amman, Jordan

ZAID A. ABDULELAH, MD
 Istishari Hospital, Amman, Jordan

AHMAD O. ARMOUTI, MD
 King Hussein Medical Center,
 Amman, Jordan

AYMAN A. ZAYED, MD, MSc, FACE, FACP
 Professor of Medicine and Chief, Division of Endocrinology,
 Diabetes, and Metabolism, Department of Internal
 Medicine, Jordan University Hospital, Amman, Jordan

A 66-year-old man with abnormal thyroid function tests

A 66-YEAR-OLD MAN presented to the emergency department with increasing shortness of breath and productive cough, which had begun 5 days earlier. Three years previously, he had been diagnosed with chronic obstructive pulmonary disease (COPD).

One week before the current presentation, he developed a sore throat, rhinorrhea, and nasal congestion, and the shortness of breath had started 2 days after that. Although he could speak in sentences, he was breathless even at rest. His dyspnea was associated with noisy breathing and cough productive of yellowish sputum; there was no hemoptysis. He reported fever, but he had no chills, night sweats, chest pain, or paroxysmal nocturnal dyspnea. The review of other systems was unremarkable.

His COPD was known to be mild, in Global Initiative for Chronic Obstructive Lung Disease (GOLD) grade 1, group A. His postbronchodilator ratio of forced expiratory volume in 1 second (FEV_1) to forced vital capacity (FVC) was less than 0.70, and his FEV_1 was 84% of predicted. Apart from mild intermittent cough with white sputum, his COPD had been under good control with inhaled ipratropium 4 times daily and inhaled albuterol as needed. He said he did not have shortness of breath except when hurrying on level ground or walking up a slight hill (Modified Medical Research Council dyspnea scale grade 1; COPD Assessment Test score < 10). In the last 3 years, he had 2 exacerbations of COPD, 1 year apart, both requiring oral prednisone and antibiotic therapy.

Other relevant history included hypertension and dyslipidemia of 15-year duration, for which he was taking candesartan 16 mg twice

daily and atorvastatin 20 mg daily. He was compliant with his medications.

Though he usually received an influenza vaccine every year, he did not get it the previous year. Also, 3 years previously, he received the 23-valent pneumococcal polysaccharide vaccine (PPSV23), and the year before that he received the pneumococcal conjugate vaccine (PCV13). In addition, he was immunized against herpes zoster and tetanus.

The patient had smoked 1 pack per day for the past 38 years. His primary care physician had advised him many times to quit smoking. He had enrolled in a smoking cessation program 2 years previously, in which he received varenicline in addition to behavioral counseling in the form of motivational interviewing and a telephone quit-line. Nevertheless, he continued to smoke.

He was a retired engineer. He did not drink alcohol or use illicit drugs.

■ PHYSICAL EXAMINATION

On physical examination, the patient was sitting up in bed, leaning forward. He was alert and oriented but was breathing rapidly and looked sick. He had no cyanosis, clubbing, pallor, or jaundice. His blood pressure was 145/90 mm Hg, heart rate 110 beats per minute and regular, respiratory rate 29 breaths per minute, and oral temperature 38.1°C (100.6°F). His oxygen saturation was 88% while breathing room air. His body mass index was 27.1 kg/m².

His throat was mildly congested. His neck veins were flat, and there were no carotid bruits. His thyroid examination was normal, without goiter, nodules, or tenderness.

Intercostal retractions were noted around the anterolateral costal margins. He had no

**He presented
with an acute
exacerbation
of COPD
requiring
hospitalization**

doi:10.3949/ccjm.86a.19024

chest wall deformities. Chest expansion was reduced bilaterally. There was hyperresonance bilaterally. Expiratory wheezes were heard over both lungs, without crackles.

His heart had no murmurs or added sounds. There was no lower-limb edema or swelling. The rest of his physical examination was unremarkable.

Chest radiography showed hyperinflation without infiltrates. Electrocardiography showed normal sinus rhythm, with a peaked P wave (P pulmonale) and evidence of right ventricular hypertrophy, but no ischemic changes.

Results of initial laboratory testing are shown in **Table 1**.

Assessment: A 66-year-old man with GOLD grade 1, group A COPD, presenting with a severe exacerbation, most likely due to viral bronchitis.

INITIAL MANAGEMENT

The patient was given oxygen 28% by Venturi mask, and his oxygen saturation went up to 90%. He was started on nebulized albuterol 2.5 mg with ipratropium bromide 500 µg every 4 hours, prednisone 40 mg orally daily for 5 days, and ceftriaxone 1 g intravenously every 24 hours. The first dose of each medication was given in the emergency department.

The patient was then admitted to a progressive care unit, where he was placed on noninvasive positive pressure ventilation, continuous cardiac monitoring, and pulse oximetry. He was started on enoxaparin 40 mg subcutaneously daily to prevent venous thromboembolism, and the oral medications he had been taking at home were continued. Because he was receiving a glucocorticoid, his blood glucose was monitored in the fasting state, 2 hours after each meal, and as needed.

Two hours after he started noninvasive positive pressure ventilation, his arterial blood gases were remeasured and showed the following results:

- pH 7.35
- Partial pressure of carbon dioxide (Paco₂) 52 mm Hg
- Bicarbonate 28 mmol/L
- Partial pressure of oxygen (Pao₂) 60 mm Hg
- Oxygen saturation 90%.

TABLE 1

Initial laboratory results

Test	Value ^a	Reference range
Hemoglobin	15.9 g/dL	13.5–17.5 g/dL
White blood cell count	16.7 x 10⁹/L	4.5–11.0 x 10 ⁹ /L
Neutrophils	85%	40%–75%
Lymphocytes	10%	20%–45%
Monocytes	3%	2%–10%
Eosinophils	1%	1%–6%
Basophils	1%	0%–1%
Platelet count	260 x 10 ⁹ /L	150–400 x 10 ⁹ /L
Sodium	136 mmol/L	135–145 mmol/L
Potassium	5.1 mmol/L	3.5–5.2 mmol/L
Blood urea nitrogen	15 mg/dL	7–20 mg/dL
Creatinine	1.0 mg/dL	0.5–1.1 mg/dL
Glucose	110 mg/dL	70–140 mg/dL
Calcium	9.5 mmol/L	8.9–10.1 mmol/L
Albumin	3.7 g/dL	3.5–5.5 g/dL
Alanine aminotransferase	32 U/L	7–35 U/L
Aspartate aminotransferase	30 U/L	7–35 U/L
Troponin I	0.21 ng/mL	0.00–0.40 ng/mL
Brain natriuretic peptide	73 pg/mL	< 125 pg/mL
Sputum gram stain	Negative	Negative
Sputum culture and sensitivity	Pending	No growth
Blood culture	Pending	No growth
Partial pressure of oxygen	54 mm Hg	75–100 mm Hg
Oxygen saturation	88%	94%–100%
Arterial blood pH	7.37	7.35–7.45
Partial pressure of carbon dioxide	50 mm Hg	35–45 mm Hg
Serum bicarbonate	28 mmol/L	22–28 mmol/L

^a Abnormal values are in bold.

HOSPITAL COURSE

On hospital day 3, his dyspnea had slightly improved. His respiratory rate was 26 to 28 breaths per minute. His oxygen saturation remained between 90% and 92%.

At 10:21 PM, his cardiac monitor showed an episode of focal atrial tachycardia at a rate

THYROID FUNCTION TESTS

TABLE 2

Thyroid function test results in patients with nonthyroidal illness

Thyroid test	Result	Mechanisms
Thyroid-stimulating hormone (TSH)	Normal, high, or low	Low TSH because of: <ul style="list-style-type: none"> • Suppression of hypothalamic-pituitary axis by inflammatory cytokines • Abnormal TSH glycosylation • Decreased leptin resulting in low thyrotropin-releasing hormone, resulting in low TSH • Increased hypothalamic and pituitary type 2 iodothyronine deiodinase (D2) activity resulting in increased local T₃ and thus decreased TSH Transient TSH increase during recovery from acute illness can be seen
Serum free thyroxine (T₄)	Normal, high, or low	Increased "direct" free T ₄ possibly because of inhibitors of T ₄ to its binding proteins ⁶ Decreased free T ₄ index possibly because of very low binding protein concentrations ⁷
Total T₄	Normal or low	Decreased total T ₄ because of: <ul style="list-style-type: none"> • Low production of its binding proteins • Decreased binding to thyroxine-binding globulin (inhibitors of T₄ binding, glycosylated thyroxine-binding globulin) • Low TSH
Total triiodothyronine (T₃)	Low	Decreased type 1 iodothyronine deiodinase (D1) activities (by cytokines, increased cortisol, free fatty acids, and drugs) Low production of thyroxine-binding globulin Decreased binding to thyroxine-binding globulin (inhibitors of T ₃ binding, glycosylated thyroxine-binding globulin) Low TSH
Reverse T₃	High ^a	Increased type 3 iodothyronine deiodinase (D3) activity Decreased D1 activity

^aExcept in patients with end-stage renal disease and in some patients with acquired immune deficiency syndrome.

of 129 beats per minute that lasted for 3 minutes and 21 seconds, terminating spontaneously. He denied any change in his clinical condition during the episode, with no chest pain, palpitation, or change in dyspnea. There was no change in his vital signs. He had another similar asymptomatic episode lasting 4 minutes and 9 seconds at 6:30 AM of hospital day 4.

Because of these episodes, the attending physician ordered thyroid function tests.

■ THYROID FUNCTION TESTING

1 Which thyroid function test is most likely to be helpful in the assessment of this patient's thyroid status?

- Serum thyroid-stimulating hormone (TSH) alone
- Serum TSH and total thyroxine (T₄)

Serum TSH and total triiodothyronine (T₃)

Serum TSH and free T₄

Serum TSH and free T₃

There are several tests to assess thyroid function: the serum TSH, total T₄, free T₄, total T₃, and free T₃ concentrations.¹

In normal physiology, TSH from the pituitary stimulates the thyroid gland to produce and secrete T₄ and T₃, which in turn inhibit TSH secretion through negative feedback. A negative log-linear relation exists between serum free T₄ and TSH levels.² Thus, the serum free T₄ level can remain within the normal reference range even if the TSH level is high or low.

TSH assays can have different detection limits. A third-generation TSH assay with a detection limit of 0.01 mU/L is recommended for use in clinical practice.³




Figure 1. Peripheral conversion of thyroxine (T_4) to triiodothyronine (T_3), reverse T_3 , and diiodothyronine (T_2) by deiodinase types 1, 2, and 3 (D1, D2, D3) in healthy people and in patients with nonthyroidal illness.

TSH testing alone. Given its superior sensitivity and specificity, serum TSH measurement is considered the best single test for assessing thyroid function in most cases.⁴ Nevertheless, measurement of the serum TSH level alone could be misleading in several situations, eg, hypothalamic or pituitary disorders, recent treatment of thyrotoxicosis, impaired sensitivity to thyroid hormone, and acute nonthyroidal illness.⁴

Because our patient is acutely ill, measuring his serum TSH alone is not the most appropriate test of his thyroid function. Euthyroid patients who present with acute illness usually have different patterns of abnormal thyroid function test results, depending on the severity of their illness, its stage, the drugs they are receiving, and other factors. Thyroid function test abnormalities in those patients are shown in **Table 2**.⁵⁻⁷

Free vs total T_4 and T_3 levels

Serum total T_4 includes a fraction that is bound, mainly to thyroxin-binding globulin, and a very small unbound (free) fraction. The same applies to T_3 . Only free thyroid hormones represent the “active” fraction available for interaction with their protein receptors in the nucleus.⁸ Patients with conditions that can affect the thyroid-binding protein concentrations usually have altered serum total T_4 and T_3 levels, whereas their free hormone concentrations remain normal. Accord-

ingly, measurement of free hormone levels, especially free T_4 , is usually recommended.

Although equilibrium dialysis is the method most likely to provide an accurate serum free T_4 measurement, it is not commonly used because of its limited availability and high cost. Thus, most commercial laboratories use “direct” free T_4 measurement or, to a lesser degree, the free T_4 index.⁹ However, none of the currently available free T_4 tests actually measure free T_4 directly; rather, they estimate it.¹⁰

Commercial laboratories can provide a direct free T_3 estimate, but it may be less reliable than total T_3 . If serum T_3 measurement is indicated, serum total T_3 is usually measured. However, total T_3 measurement is rarely indicated for patients with hypothyroidism because it usually remains within the normal reference range.¹¹ Nevertheless, serum total T_3 measurement could be useful in patients with T_3 toxicosis and in those who are acutely ill.

Accordingly, in acutely ill hospitalized patients like ours, measuring serum TSH using a third-generation assay and free T_4 is essential to assess thyroid function. Many clinicians also measure serum total T_3 .

■ CASE CONTINUED: LOW TSH, LOW-NORMAL FREE T_4 , LOW TOTAL T_3

The attending physician ordered serum TSH, free T_4 , and total T_3 measurements, which

On hospital days 3 and 4, he had 2 episodes of focal atrial tachycardia

TABLE 3

Clinical causes of decreased D1 activity

Condition or drug	Comment
Low caloric intake, malnutrition	The most common inhibitory factor of type 1 iodothyronine deiodinase (D1)
Nonthyroid illness	Even if it is mild
Drugs	
Propylthiouracil	Not methimazole
Glucocorticoids	Eg, 4 mg of dexamethasone decreases total T ₃ by 30% in several days
Beta-adrenergic antagonists	Propranolol, metoprolol, atenolol, and alprenolol (not nadolol or sotalol)
Oral cholecystographic agents (eg, sodium ipodate)	Not available in United States
Amiodarone	Could compete with thyroxine (T ₄) for the deiodinative site
Liver disease	Liver tissue expresses high levels of D1
Selenium deficiency	D1 is a selenoprotein
Neonatal period	Especially in premature and low-birth-weight infants

yielded the following:

- TSH 0.1 mU/L (0.5–5.0)
- Total T₃ 55 ng/dL (80–180)
- Free T₄ 0.9 ng/dL (0.9–2.4).

2 Which best explains this patient’s abnormal thyroid test results?

- His acute illness
- Central hypothyroidism due to pituitary infarction
- His albuterol therapy
- Subclinical thyrotoxicosis
- Hashimoto thyroiditis

Since euthyroid patients with an acute illness may have abnormal thyroid test results (Table 2),^{5–7} thyroid function testing is not recommended unless there is a strong indication for it, such as new-onset atrial fibrillation, atrial flutter, or focal atrial tachycardia.¹ In such patients, it is important to know whether the test abnormalities represent true thyroid disorder or are the result of a nonthyroidal illness.

In healthy people, T₄ is converted to T₃ (the principal active hormone) by type 1 deiodinase (D1) mainly in the liver and kidneys, whereas this reaction is catalyzed by type 2 deiodinase (D2) in the hypothalamus and pituitary. Type 3 deiodinase (D3) converts T₄ to reverse T₃, a biologically inactive molecule.¹² D1 also mediates conversion of reverse T₃ to diiodothyronine (T₂) (Figure 1).

Several conditions and drugs can decrease D1 activity, resulting in low serum T₃ concentrations (Table 3). In patients with nonthyroidal illness, decreased D1 activity can be observed as early as the first 24 hours after the onset of the illness and is attributed to increased inflammatory cytokines, free fatty acids, increased endogenous cortisol secretion, and use of certain drugs.^{13,14} In addition, the reduced D1 activity can decrease the conversion of reverse T₃ to T₂, resulting in elevated serum reverse T₃. Increased D3 activity during an acute illness is another mechanism for elevated serum reverse T₃ concentration.¹⁵

Thyroid function testing in patients with nonthyroidal illness usually shows low serum total T₃, normal or low serum TSH, and normal, low, or high serum free T₄. However, transient mild serum TSH elevation can be seen in some patients during the recovery period.¹⁶ These abnormalities with their mechanisms are shown in Table 2.^{5–7} In several commercial kits, serum direct free T₄ can be falsely decreased or increased.⁸

THE DIFFERENTIAL DIAGNOSIS

Our patient had low serum TSH, low-normal serum direct free T₄, and low serum total T₃. This profile could be caused by a nonthyroidal illness, “true” central hypothyroidism, or his glucocorticoid treatment. The reason we

What could account for his low TSH, low-normal free T₄, and low total T₃ levels?

use the term “true” in this setting is that some experts suggest that the thyroid function test abnormalities in patients with acute nonthyroidal illness represent a transient central hypothyroidism.¹⁷ The clinical presentation is key in differentiating true central hypothyroidism from nonthyroidal illness.

In addition, measuring serum cortisol may help to differentiate between the 2 states, as it would be elevated in patients with nonthyroidal illness as part of a stress response but low in patients with true central hypothyroidism, since it is usually part of combined pituitary hormone deficiency.¹⁸ Of note, some critically ill patients have low serum cortisol because of transient central adrenal insufficiency.^{19,20}

The serum concentration of reverse T_3 has been suggested as a way to differentiate between hypothyroidism (low) and nonthyroidal illness (high); however, further studies showed that it does not reliably differentiate between the conditions.²¹

■ GLUCOCORTICOIDS AND THYROID FUNCTION TESTS

By inhibiting D1, glucocorticoids can decrease peripheral conversion of T_4 to T_3 and thus decrease serum total T_3 . This effect depends on the type and dose of the glucocorticoid and the duration of therapy.

In one study,²² there was a significant reduction in serum total T_3 concentration 24 hours after a single oral dose of dexamethasone 12 mg in normal participants. This effect lasted 48 hours, after which serum total T_3 returned to its pretreatment level.

In another study,²³ a daily oral dose of beta-methasone 1.5 mg for 5 days did not significantly reduce the serum total T_3 in healthy volunteers, but a daily dose of 3 mg did. This effect was more pronounced at a daily dose of 4.5 mg, whereas a dose of 6.0 mg had no further effect.

Long-term glucocorticoid therapy also decreases serum total T_4 and total T_3 by lowering serum thyroid-binding globulin.²⁴

Finally, glucocorticoids can decrease TSH secretion by directly inhibiting thyrotropin-releasing hormone.^{25,26} However, chronic hypercortisolism, whether endogenous or exogenous, does not cause clinically central hypothyroidism, possibly because of the negative

feedback mechanism of low thyroid hormones on the pituitary and the hypothalamus.²⁷

Other drugs including dopamine, dopamine agonists, dobutamine, and somatostatin analogues can suppress serum TSH. As with glucocorticoids, these drugs do not cause clinically evident central hypothyroidism.²⁸ Bexarotene, a retinoid X receptor ligand used in the treatment of cutaneous T-cell lymphoma, has been reported to cause clinically evident central hypothyroidism by suppressing TSH and increasing T_4 clearance.²⁹

■ BETA-BLOCKERS, BETA-AGONISTS AND THYROID FUNCTION

While there is general agreement that beta-adrenergic antagonists (beta-blockers) do not affect the serum TSH concentration, conflicting data have been reported concerning their effect on other thyroid function tests. This may be due to several factors, including dose, duration of therapy, the patient's thyroid status, and differences in laboratory methodology.³⁰

In studies of propranolol, serum total T_4 concentrations did not change or were increased with daily doses of 160 mg or more in both euthyroid participants and hyperthyroid patients³¹⁻³³; serum total T_3 concentrations did not change or were decreased with 40 mg or more daily³⁴; and serum reverse T_3 concentrations were increased with daily doses of 80 mg or more.³¹ It is most likely that propranolol exerts these changes by inhibiting D1 activity in peripheral tissues.

Furthermore, a significant decrease in serum total T_3 concentrations was observed in hyperthyroid patients treated with atenolol 100 mg daily, metoprolol 100 mg daily, and alprenolol 100 mg daily, but not with sotalol 80 mg daily or nadolol (up to 240 mg daily).^{35,36}

On the other hand, beta-adrenergic agonists have not been reported to cause significant changes in thyroid function tests.³⁷

■ SUBCLINICAL THYROTOXICOSIS OR HASHIMOTO THYROIDITIS?

Our patient's thyroid function test results are more likely due to his nonthyroidal illness and glucocorticoid therapy, as there is no clinical evidence to point to a hypothalamic-pituitary

Acute illness can alter thyroid test results by several mechanisms

disorder accounting for true central hypothyroidism.

The other options mentioned in question 2 are unlikely to explain our patient's thyroid function test results.

Subclinical thyrotoxicosis is characterized by suppressed serum TSH, but both serum free T_4 and total T_3 remain within the normal reference ranges. In addition, the serum TSH level may help to differentiate between thyrotoxicosis and nonthyroidal illness. In the former, serum TSH is usually suppressed (< 0.01 mU/L), whereas in the latter it is usually low but detectable (0.05–0.3 mU/L).^{38,39}

Hashimoto thyroiditis is a chronic autoimmune thyroid disease characterized by diffuse lymphocytic infiltration of the thyroid gland. Almost all patients with Hashimoto thyroiditis have elevated levels of antibodies to thyroid peroxidase or thyroglobulin.⁴⁰ Clinically, patients with Hashimoto thyroiditis can either be hypothyroid or have normal thyroid function, which is not the case in our patient.

■ CASE CONTINUED

An endocrinologist, consulted for a second opinion, agreed that the patient's thyroid function test results were most likely due to his nonthyroidal illness and glucocorticoid therapy.

3 In view of the endocrinologist's opinion, which should be the next step in the management of the patient's thyroid condition?

- Start levothyroxine (T_4) therapy
- Start liothyronine (T_3) therapy
- Start *N*-acetylcysteine therapy
- Start thyrotropin-releasing hormone therapy
- Remeasure thyroid hormones after full recovery from his acute illness

It is not clear whether the changes in thyroid hormone levels during an acute illness are a pathologic alteration for which thyroid hormone therapy may be beneficial, or a physiologic adaptation for which such therapy would not be indicated.⁴¹

However, current data argue against thyroid hormone therapy using T_4 or T_3 for patients with nonthyroidal illness syndrome (also called euthyroid sick syndrome).⁴² In-

deed, several randomized controlled trials showed that thyroid hormone therapy is not beneficial in such patients and may be detrimental.^{41,43}

Therapies other than thyroid hormone have been investigated to ameliorate thyroid hormone abnormalities in patients with nonthyroidal illness. These include *N*-acetylcysteine, thyrotropin-releasing hormone therapy, and nutritional support.

Some studies showed that giving *N*-acetylcysteine, an antioxidant, increased serum T_3 and decreased serum reverse T_3 concentrations in patients with acute myocardial infarction.⁴⁴ Nevertheless, the mortality rate and length of hospitalization were not affected. Further studies are needed to know whether *N*-acetylcysteine therapy is beneficial for such patients.

Similarly, a study using a thyrotropin-releasing hormone analogue along with growth hormone-releasing peptide 2 showed an increase in serum TSH, T_4 , and T_3 levels in critically ill patients.⁴⁵ The benefit of this therapy has yet to be determined. On the other hand, early nutritional support was reported to prevent thyroid hormonal changes in patients postoperatively.⁴⁶

Measuring thyroid hormone levels after full recovery is the most appropriate next step in our patient, as the changes in thyroid hormone concentrations subside as the acute illness resolves.⁴⁷

■ CASE CONTINUED

The patient continued to improve. On hospital day 6, he was feeling better but still had mild respiratory distress. There had been no further episodes of arrhythmia since day 4. His blood pressure was 136/86 mm Hg, heart rate 88 beats per minute and regular, respiratory rate 18 breaths per minute, and oral temperature 37.1°C. His oxygen saturation was 92% on room air.

Before discharge, he was encouraged to quit smoking. He was offered behavioral counseling and medication therapy, but he only said that he would think about it. He was discharged on oral cefixime for 4 more days and was instructed to switch to a long-acting bronchodilator along with his other home

After illness, normalization of thyroid test results can take weeks or months

medications and to return in 1 week to have his thyroid hormones checked.

One week later, his laboratory results were:

- TSH 11.2 mU/L (reference range 0.5–5.0)
- Free T₄ 1.2 ng/dL (0.9–2.4)
- Total T₃ 92 ng/dL (80–180).

Clinically, the patient was euthyroid, and examination of his thyroid was unremarkable.

4 Based on these last test results, which statement is correct?

- Levothyroxine therapy should be started
- His serum TSH elevation is most likely transient
- Thyroid ultrasonography is strongly indicated
- A radioactive iodine uptake study should be performed
- Measurement of thyroid-stimulating immunoglobulins is indicated

During recovery from nonthyroidal illness, some patients may have elevated serum TSH levels that are usually transient and modest (< 20 mU/L).⁴⁸ Normalization of the thyroid function tests including serum TSH may take several weeks⁴⁹ or months.⁵⁰ However, a systematic review found that the likelihood of permanent primary hypothyroidism is high in patients with serum TSH levels higher than 20 mU/L during the recovery phase of their nonthyroidal illness.⁵¹

Ultrasonography is useful for evaluating patients with thyroid nodules or goiter but is of little benefit for patients like ours, in whom the thyroid is normal on examination.

Similarly, a radioactive iodine uptake study is not indicated, as it is principally used to help differentiate between types of thyrotoxicosis. (Radioactive iodine is also used to treat differentiated thyroid cancer.)

Thyroid-stimulating immunoglobulins are TSH receptor-stimulating antibodies that cause Graves disease. Nevertheless, measuring them is not routinely indicated for its diagnosis. However, their measurement is of significant help in the diagnosis of Graves disease if a radioactive iodine uptake study cannot be performed (as in pregnancy) and in atypical presentations such as euthyroid Graves ophthalmopathy.⁵² Other indications for thyroid-

stimulating immunoglobulin measurement are beyond the scope of the article. Our patient's test results are not consistent with hyperthyroidism, so measuring thyroid-stimulating immunoglobulins is not indicated.

■ CASE CONCLUSION: BETTER, BUT STILL SMOKING

The patient missed his 1-month clinic follow-up, but he visited the clinic for follow-up 3 months later. He was feeling well with no complaints. Test results including serum TSH, free T₄, and total T₃ were within normal ranges. His COPD was under control, with an FEV₁ 88% of predicted.

He was again encouraged to quit smoking and was offered drug therapy and behavioral counseling, but he declined. In addition, he was instructed to adhere to his annual influenza vaccination.

■ KEY POINTS

- In patients with acute illness, it is recommended that thyroid function not be assessed unless there is a strong indication.
- If thyroid function assessment is indicated for critically ill patients, serum TSH and free T₄ concentrations should be measured. Some clinicians also measure serum total T₃ level.
- Thyroid function testing in critically ill patients usually shows low serum total T₃, normal or low serum TSH, and normal or low serum free T₄.
- Many drugs can alter thyroid hormone levels.
- Thyroid hormone therapy is not recommended for critically ill patients with low T₃, low T₄, or both.
- During recovery from nonthyroidal illness, some patients may have mild elevation in serum TSH levels (< 20 mU/L).
- Thyroid hormone levels may take several weeks or months to return to normal after the acute illness.
- Patients with serum TSH levels higher than 20 mU/L during the recovery phase of their nonthyroidal illness are more likely to have permanent primary hypothyroidism. ■

3 months later, he was feeling well; he had no complaints, and his free T₄, TSH, and total T₃ were normal

REFERENCES

1. **Lamb EJ, Martin J.** Thyroid function tests: often justified in the acutely ill. *Ann Clin Biochem* 2000; 37(pt 2):158–164. doi:10.1258/0004563001899159
2. **Spencer CA, LoPresti JS, Patel A, et al.** Applications of a new chemiluminometric thyrotropin assay to subnormal measurement. *J Clin Endocrinol Metab* 1990; 70(2):453–460. doi:10.1210/jcem-70-2-453
3. **Ross DS, Ardisson LJ, Meskell MJ.** Measurement of thyrotropin in clinical and subclinical hyperthyroidism using a new chemiluminescent assay. *J Clin Endocrinol Metab* 1989; 69(3):684–688. doi:10.1210/jcem-69-3-684
4. **Koulouri O, Moran C, Halsall D, Chatterjee K, Gurnell M.** Pitfalls in the measurement and interpretation of thyroid function tests. *Best Pract Res Clin Endocrinol Metab* 2013; 27(6):745–762. doi:10.1016/j.beem.2013.10.003
5. **Lechan RM, Fekete C.** Role of thyroid hormone deiodination in the hypothalamus. *Thyroid* 2005; 15(8):883–897. doi:10.1089/thy.2005.15.883
6. **Chopra IJ, Hershman JM, Partridge WM, Nicoloff JT.** Thyroid function in nonthyroidal illnesses. *Ann Intern Med* 1983; 98(6):946–957. doi:10.7326/0003-4819-98-6-946
7. **Chopra IJ, Solomon DH, Hepner HW, Mortenstein AA.** Misleadingly low free thyroxine index and usefulness of reverse triiodothyronine measurement in nonthyroidal illnesses. *Ann Intern Med* 1979; 90(6):905–912. doi:10.7326/0003-4819-90-6-905
8. **Pontecorvi A, Robbins J.** The plasma membrane and thyroid hormone entry into cells. *Trends Endocrinol Metab* 1989; 1(2):90–94. PMID:18411097
9. **Hennemann G, Krenning EP.** Pitfalls in the interpretation of thyroid function tests in old age and non-thyroidal illness. *Horm Res* 1987; 26(1–4):100–104. doi:10.1159/000180688
10. **Baloch Z, Carayon P, Conte-Devolx B, et al; Guidelines Committee, National Academy of Clinical Biochemistry.** Laboratory medicine practice guidelines. Laboratory support for the diagnosis and monitoring of thyroid disease. *Thyroid* 2003; 13(1):3–126. doi:10.1089/105072503321086962
11. **Lum S, Nicoloff JT, Spencer CA, Kaptein EM.** Peripheral tissue mechanism for maintenance of serum triiodothyronine values in a thyroxine-deficient state in man. *J Clin Invest* 1984; 73(2):570–575. doi:10.1172/JCI111245
12. **Ortiga-Carvalho TM, Chiamolera MI, Pazos-Moura CC, Wondisford FE.** Hypothalamus-pituitary-thyroid axis. *Compr Physiol* 2016; 6(3):1387–1428. doi:10.1002/cphy.c150027
13. **de Vries EM, Fliers E, Boelen A.** The molecular basis of the non-thyroidal illness syndrome. *J Endocrinol* 2015; 225(3):R67–R81. doi:10.1530/JOE-15-0133
14. **Chopra IJ, Huang TS, Beredo A, Solomon DH, Teco GN, Mean JF.** Evidence for an inhibitor of extrathyroidal conversion of thyroxine to 3, 5, 3'-triiodothyronine in sera of patients with nonthyroidal illnesses. *J Clin Endocrinol Metab* 1985; 60(4):666–672. doi:10.1210/jcem-60-4-666
15. **Peeters RP, Debaveye Y, Fliers E, Visser TJ.** Changes within the thyroid axis during critical illness. *Crit Care Clin* 2006; 22(1):41–55. doi:10.1016/j.ccc.2005.08.006
16. **Spencer C, Eigen A, Shen D, et al.** Specificity of sensitive assays of thyrotropin (TSH) used to screen for thyroid disease in hospitalized patients. *Clin Chem* 1987; 33(8):1391–1396. PMID:3301067
17. **Adler SM, Wartofsky L.** The nonthyroidal illness syndrome. *Endocrinol Metab Clin North Am* 2007; 36(3):657–672. doi:10.1016/j.ecl.2007.04.007
18. **Persani L.** Central hypothyroidism: pathogenic, diagnostic, and therapeutic challenges. *J Clin Endocrinol Metab* 2012; 97(9):3068–3078. doi:10.1210/jc.2012-1616
19. **Kidess AI, Caplan RH, Reynertson RH, Wickus GG, Goodnough DE.** Transient corticotropin deficiency in critical illness. *Mayo Clin Proc* 1993; 68(5):435–441. doi:10.1016/s0025-6196(12)60188-8
20. **Lamberts SW, Bruining HA, De Jong FH.** Corticosteroid therapy in severe illness. *N Engl J Med* 1997; 337(18):1285–1292. doi:10.1056/NEJM199710303371807
21. **Burmeister LA.** Reverse T3 does not reliably differentiate hypothyroid sick syndrome from euthyroid sick syndrome. *Thyroid* 1995; 5(6):435–441. doi:10.1089/thy.1995.5.435
22. **Duick DS, Warren DW, Nicoloff JT, Otis CL, Croxson MS.** Effect of single dose dexamethasone on the concentration of serum triiodothyronine in man. *J Clin Endocrinol Metab* 1974; 39(6):1151–1154. doi:10.1210/jcem-39-6-1151
23. **Gamstedt A, Järnerot G, Kågedal B.** Dose related effects of betamethasone on iodothyronines and thyroid hormone-binding proteins in serum. *Acta Endocrinol (Copenh)* 1981; 96(4):484–490. doi:10.1530/acta.0.0960484
24. **Wartofsky L, Burman KD.** Alterations in thyroid function in patients with systemic illness: the “euthyroid sick syndrome.” *Endocr Rev* 1982; 3(2):164–217. doi:10.1210/edrv-3-2-164
25. **Wilber JF, Utiger RD.** The effect of glucocorticoids on thyrotropin secretion. *J Clin Invest* 1969; 48(11):2096–2103. doi:10.1172/JCI106176
26. **Nicoloff JT, Fisher DA, Appleman MD Jr.** The role of glucocorticoids in the regulation of thyroid function in man. *J Clin Invest* 1970; 49(10):1922–1929. doi:10.1172/JCI106411
27. **Surks MI, Sievert R.** Drugs and thyroid function. *N Engl J Med* 1995; 333(25):1688–1694. doi:10.1056/NEJM199512213332507
28. **Haugen BR.** Drugs that suppress TSH or cause central hypothyroidism. *Best Pract Res Clin Endocrinol Metab* 2009; 23(6):793–800. doi:10.1016/j.beem.2009.08.003
29. **Sherman SI, Gopal J, Haugen BR, et al.** Central hypothyroidism associated with retinoid X receptor-selective ligands. *N Engl J Med* 1999; 340(14):1075–1079. doi:10.1056/NEJM199904083401404
30. **Murchison LE, How J, Bewsher PD.** Comparison of propranolol and metoprolol in the management of hyperthyroidism. *Br J Clin Pharmacol* 1979; 8(6):581–587. doi:10.1111/j.1365-2125.1979.tb01048.x
31. **Faber J, Friis T, Kirkegaard C, et al.** Serum T4, T3 and reverse T3 during treatment with propranolol in hyperthyroidism, L-T4 treated myxedema and in normal man. *Horm Metab Res* 1979; 11(1):34–36. doi:10.1055/s-0028-1092678
32. **Kristensen BO, Weeke J.** Propranolol-induced increments in total and free serum thyroxine in patients with essential hypertension. *Clin Pharmacol Ther* 1977; 22(6):864–867. doi:10.1002/cpt.1977226864
33. **Murchison LE, Bewsher PD, Chesters MI, Ferrier WR.** Comparison of propranolol and practolol in the management of hyperthyroidism. *Br J Clin Pharmacol* 1976; 3(2):273–277. doi:10.1111/j.1365-2125.1976.tb00603.x
34. **Lotti G, Delitala G, Devilla L, Alagna S, Masala A.** Reduction of plasma triiodothyronine (T3) induced by propranolol. *Clin Endocrinol* 1977; 6(6):405–410. doi:10.1111/j.1365-2265.1977.tb03322.x
35. **Perrild H, Hansen JM, Skovsted L, Christensen LK.** Different effects of propranolol, alprenolol, sotalol, atenolol and metoprolol on serum T3 and serum rT3 in hyperthyroidism. *Clin Endocrinol (Oxf)* 1983; 18(2):139–142. PMID:6133659
36. **Reeves RA, From GL, Paul W, Leenen FH.** Nadolol, propranolol, and thyroid hormones: evidence for a membrane-stabilizing action of propranolol. *Clin Pharmacol Ther* 1985; 37(2):157–161. doi:10.1038/clpt.1985.28
37. **Walker N, Jung RT, Jennings G, James WP.** The effect of a beta-receptor agonist (salbutamol) on peripheral thyroid metabolism in euthyroid subjects. *Horm Metab Res* 1981; 13(10):590–591. doi:10.1055/s-2007-1019346
38. **Melmed S, Geola FL, Reed AW, Pekary AE, Park J, Hershman JM.** A comparison of methods for assessing thyroid function in nonthyroidal illness. *J Clin Endocrinol Metab* 1982; 54(2):300–306. doi:10.1210/jcem-54-2-300
39. **Docter R, Krenning E, De Jong M, Hennemann G.** The sick euthyroid syndrome: changes in thyroid hormone serum parameters and hormone metabolism. *Clin Endocrinol (Oxf)* 1993; 39(5):499–518. PMID:8252737
40. **Mariotti S, Catregli P, Piccolo P, Barbesino G, Pinchera A.** Antithyroid peroxidase autoantibodies in thyroid diseases. *J Clin Endocrinol Metab* 1990; 71(3):661–669. doi:10.1210/jcem-71-3-661

41. **De Groot LJ.** Non-thyroidal illness syndrome is a manifestation of hypothalamic-pituitary dysfunction, and in view of current evidence, should be treated with appropriate replacement therapies. *Crit Care Clin* 2006; 22(1):57–86. doi:10.1016/j.ccc.2005.10.001
42. **Jonklaas J, Bianco AC, Bauer AJ, et al; American Thyroid Association Task Force on Thyroid Hormone Replacement.** Guidelines for the treatment of hypothyroidism: prepared by the American Thyroid Association Task Force on Thyroid Hormone Replacement. *Thyroid* 2014; 24(12):1670–1751. doi:10.1089/thy.2014.0028.
43. **Kaptein EM, Beale E, Chan LS.** Thyroid hormone therapy for obesity and nonthyroidal illnesses: a systematic review. *J Clin Endocrinol Metab* 2009; 94(10):3663–3675. doi:10.1210/jc.2009-0899
44. **Vidart J, Wajner SM, Leite RS, et al.** N-acetylcysteine administration prevents nonthyroidal illness syndrome in patients with acute myocardial infarction: a randomized clinical trial. *J Clin Endocrinol Metab* 2014; 99(12):4537–4545. doi:10.1210/jc.2014-2192
45. **Van den Berghe G, Wouters P, Weekers F, et al.** Reactivation of pituitary hormone release and metabolic improvement by infusion of growth hormone-releasing peptide and thyrotropin-releasing hormone in patients with protracted critical illness. *J Clin Endocrinol Metab* 1999; 84(4):1311–1323. doi:10.1210/jcem.84.4.5636
46. **Langouche L, Vander Perre S, Marques M, et al.** Impact of early nutrient restriction during critical illness on the nonthyroidal illness syndrome and its relation with outcome: a randomized, controlled clinical study. *J Clin Endocrinol Metab* 2013; 98(3):1006–1013. doi:10.1210/jc.2012-2809
47. **Economidou F, Douka E, Tzanela M, Nanas S, Kotanidou A.** Thyroid function during critical illness. *Hormones (Athens)* 2011; 10(2):117–124. doi:10.14310/horm.2002.1301
48. **Hamblin PS, Dyer SA, Mohr VS, et al.** Relationship between thyrotropin and thyroxine changes during recovery from severe hypothyroxinemia of critical illness. *J Clin Endocrinol Metab* 1986; 62(4):717–722. doi:10.1210/jcem-62-4-717
49. **Iglesias P, Diez JJ.** Thyroid dysfunction and kidney disease. *Eur J Endocrinol* 2009; 160(4):503–515. doi:10.1530/EJE-08-0837
50. **Spencer CA.** Clinical utility and cost-effectiveness of sensitive thyrotropin assays in ambulatory and hospitalized patients. *Mayo Clin Proc* 1988; 63(12):1214–1222. doi:10.1016/s0025-6196(12)65408-1
51. **Attia J, Margetts P, Guyatt G.** Diagnosis of thyroid disease in hospitalized patients: a systematic review. *Arch Intern Med* 1999; 159(7):658–665. pmid:10218744
52. **Barbesino G, Tomer Y.** Clinical review: clinical utility of TSH receptor antibodies. *J Clin Endocrinol Metab* 2013; 98(6):2247–2255. doi:10.1210/jc.2012-4309

ADDRESS: Ayman A. Zayed, MD, MSc, FACE, FACP, Department of Internal Medicine, Jordan University Hospital, Queen Rania Street, Amman, Jordan, 11942; baraaayman@gmail.com



Pulmonary Hypertension Summit 2019

Earn
ABIM MOC Points

The Summit will provide you with an overview of the practical issues in the diagnosis, evaluation, and management of patients with pulmonary hypertension. The Summit will synthesize the World Symposia on Pulmonary Hypertension proceedings. Expert speakers will present the most recent advances in the context of challenges faced by physicians and other health care providers caring for these patients.


Key Features

- Learn from shared experts broadcast between two locations – Cleveland, OH and Fort Lauderdale, FL
- Expand and enhance decision-making skills in highly complex clinical situations through case discussions
- Increase your confidence to devise and implement effective treatment plans for patients
- Learn available combination therapies and how to incorporate them into patient care strategies
- New this year in Cleveland - optional pulmonary hypertension clinical immersion hands on workshop
- Live online stream available for those who can't attend in person

This activity has been approved for
AMA PRA Category 1 Credit™.

November 7-8, 2019

- ▶ InterContinental Hotel and Bank of America Conference Center
Cleveland, OH
- ▶ Sonesta Fort Lauderdale Fort Lauderdale, FL



Register Today! www.ccfcm.org/PH2019